ArticleAsian Pacific journal of cancer prevention : APJCP2026
Quinoxaline as Dual Modulators of Apoptotic Regulators Bcl-2 and Bax: A Combined In Vitro and In Silico Anticancer Approach.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the antioxidant potential of quinoxaline and investigate its molecular interactions with cancer-related proteins through computational docking.
methodsAntioxidant activity of quinoxaline was assessed using DPPH, FRAP, ABTS, hydrogen peroxide, superoxide, and reducing power assays at varying concentrations, and IC₅₀ values were calculated. Molecular docking studies were performed to examine the interactions of quinoxaline with cancer-associated proteins, including epidermal growth factor receptor (EGFR), B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and β-actin.
resultsAntioxidant assays showed a concentration-dependent increase in inhibitory activity, with IC₅₀ values of 130.446 µM (DPPH), 151.343 µM (FRAP), 171.551 µM (ABTS), 108.194 µM (H₂O₂), 104.592 µM (superoxide), and 95.893 µM (reducing power assay). Molecular docking analysis revealed that quinoxaline exhibited strong binding affinity with the anti-apoptotic Bcl-2, suggesting potential inhibition of its function. Additionally, favorable interactions with the pro-apoptotic Bax were observed, indicating a possible dual mechanism of apoptosis induction.
conclusionQuinoxaline demonstrated significant antioxidant activity and potential pro-apoptotic effects by targeting key apoptotic regulators. The docking results suggest that quinoxaline could inhibit anti-apoptotic Bcl-2 while promoting the activity of the pro-apoptotic Bax, thereby inducing apoptosis and highlighting its potential as a promising anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.